Cell Medica raises £50 million

London-based Cell Medica Ltd has raised £50 million from institutional investors to support development of its lead oncology product, CMD-003, for the treatment of patients with advanced lymphomas associated with the Epstein Barr virus.

Go to the profile of Victoria English
Nov 26, 2014
0
0
Upvote 0 Comment

London-based Cell Medica Ltd has raised £50 million from institutional investors to support development of its lead oncology product, CMD-003, for the treatment of patients with advanced lymphomas associated with the Epstein Barr virus.

The Series B funding round was led by Imperial Innovations, which is a listed technology transfer group, and co-led by Invesco Asset Management and Woodford Investment Management.

Cell Medica was founded in 2007 with financial support from the Wellcome Trust to investigate cellular immunotherapies for the treatment of cancer and infectious disease. Its first product Cytovir uses immune cells from a healthy donor to restore immunity to cytomegalovirus infections in patients who have lost their immunity following a bone marrow transplant. This product is available in the UK at a clinician’s request. The company’s lead oncology product for patients with advanced lymphomas isunder investigation in a Phase 2 trial. The product, Cytorex EBV (CMD-003), is comprised of the patient’s own immune cells. The financing for this trial is being provided in part by the Cancer Prevention and Research Institute of Texas.

Imperial Innovations announced the financing on 25 November 2014.

Copyright 2014 Evernow Publishing Ltd

Go to the profile of Victoria English

Victoria English

Editor, MedNous, a publication of Evernow Publishing Ltd

Co-founder and editor of Evernow Publishing Ltd. International journalist with previous full-time editorial positions at Informa Plc, Thomson Reuters, McGraw-Hill and Dow Jones Inc. Have worked as a correspondent covering finance in New York, Amsterdam, Brussels and London, and covering healthcare and the life sciences in London.

No comments yet.